课题基金 / 基金详情

CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)

CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)
卡罗莱纳州癌症纳米技术培训计划 (C-CNTP)
批准号:
10650745
负责人:
ALEXANDER V KABANOV
金额:
$38.86万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-07-01 至 2025-06-30

项目摘要

项目成果

ALEXANDER V KABANOV的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This proposal seeks competing continuation of the NIH T32 Carolina Cancer Nanotechnology Training Program (C-CNTP). The program started in 2015 with the support of the NIH Ruth L. Kirschstein National Research Service Award. The goal of the program is to make a major contribution to the growth of the cancer nanotechnology workforce by providing training and research experience to a highly select cohort of postdoctoral fellows. During four years since its initiation the program has recruited 15 excellent fellows of whom 5 have completed training and moved into tenure track assistant professors, industry and FDA positions, 8 continue training with the NIH T32 support and 2 are in the final stages of training with other support sources in the labs of their mentors. We have assembled a team of 20 outstanding Program faculty from 11 departments and 3 schools at the University of North Carolina Chapel Hill with specific expertise in physical and material sciences, chemistry, pharmacoengineering, drug delivery, computational modeling as well as basic biomedical research and clinical science, all of whom have demonstrated strong interests, capabilities and collaborations at the interface between nanoscience and cancer. The objectives of the C-CNTP are to: 1) recruit an elite group of talented postdoctoral fellows from diverse backgrounds with PhD, MD or PharmD and provide them with outstanding postdoctoral experience including focused didactic training and co-mentored research experience with faculty mentors from complementary fields; 2) provide each trainee with intensive introductory training with online video library of recorded lectures followed by workshops and didactic courses to remediate differences in their backgrounds and to deepen the knowledge and understanding in the key areas of cancer nanotechnology; and 3) facilitate transition of trainees to independence by providing them with opportunities to a) conduct original cancer nanotechnology research projects; b) apply for the individual cancer nanotechnology Pilot Grants within C-CNTP, and c) acquire written and oral communications skills needed to publish manuscripts, report results, and write successful individual extramural support applications focused on problems of cancer nanotechnology. We are committed to developing a world-class postdoctoral training program that capitalizes on the existing strengths in cancer nanotechnology research, consolidates diverse research and education resources across several academic units, and becomes a significant contributor to addressing the Nation's research needs in cancer nanotechnology.
期刊论文(29)
专著(0)
科研奖励(0)
会议论文
Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents.
肺腺癌原位同基因模型的制备以及化疗和免疫治疗剂聚(2-恶唑啉)制剂的抗肿瘤功效测试。
DOI: 10.21769/bioprotoc.3953
发表时间: 2021
期刊: Bio-protocol
影响因子: 0.8
作者: [Vinod,Natasha, Hwang,Duhyeong, Azam,SalmaH, VanSwearingen,AmandaED, Wayne,Elizabeth, Fussell,SloaneChristian, Sokolsky-Papkov,Marina, Pecot,ChadV, Kabanov,AlexanderV]
通讯作者: Kabanov,AlexanderV
DOI: 10.3389/fphar.2018.00307
发表时间: 2018
期刊: Frontiers in pharmacology
影响因子: 5.6
作者: [Harrison EB, Azam SH, Pecot CV]
通讯作者: Pecot CV
DOI: 10.4049/jimmunol.2001287
发表时间: 2021-06-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Sandor AM, Sturdivant MS, Ting JPY]
通讯作者: Ting JPY
Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.
纤维蛋白凝胶增强胶质母细胞瘤中嵌合抗原受体 T 细胞的抗肿瘤作用。
DOI: 10.1126/sciadv.abg5841
发表时间: 2021-10-08
期刊: Science advances
影响因子: 13.6
作者: [Ogunnaike EA, Valdivia A, Yazdimamaghani M, Leon E, Nandi S, Hudson H, Du H, Khagi S, Gu Z, Savoldo B, Ligler FS, Hingtgen S, Dotti G]
通讯作者: Dotti G
23
    Naturally Targeted Exosomal TLR7/8 Agonist for Immunotherapy of Medulloblastoma
    • 批准号:
      10790660
    • 项目类别:
    • 资助金额:
      $42.76万
    • 财政年份:
      2023
    • 负责人:
      ALEXANDER V KABANOV
    • 依托单位:
    TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
    • 批准号:
      10436355
    • 项目类别:
    • 资助金额:
      $60.08万
    • 财政年份:
      2021
    • 负责人:
      ALEXANDER V KABANOV
    • 依托单位:
    TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
    • 批准号:
      10684815
    • 项目类别:
    • 资助金额:
      $49.63万
    • 财政年份:
      2021
    • 负责人:
      ALEXANDER V KABANOV
    • 依托单位:
    TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
    • 批准号:
      10621403
    • 项目类别:
    • 资助金额:
      $11.79万
    • 财政年份:
      2021
    • 负责人:
      ALEXANDER V KABANOV
    • 依托单位:
    海外基金